

Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter [here >](#)



CLINICAL TRIALS ARENA




NEWS

Novartis' Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial

24 Aug 2021 (Last Updated August 24th, 2021 15:01)

The safety profile of the drug in the Phase III BELINDA trial was in line with the already reported data.



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

[Continue](#) [Learn more](#)

Novartis has reported that Kymriah (tisagenlecleucel) failed to meet the primary goal of the Phase III BELINDA clinical trial in aggressive B-cell non-Hodgkin lymphoma (NHL) patients who relapsed or did not respond to first-line therapy.

Kymriah is a cluster of differentiation 19 (CD-19)-targeting genetically altered autologous T-cell immunotherapy.

Developed in partnership with the Perelman School of Medicine at the University of Pennsylvania, Kymriah is the first CAR-T cell therapy to obtain approval.

SPONSORED ARTICLE

Survival of the fittest: How e-commerce can help define the future of fuel retail

[Read More](#)

SPONSORED WHITE PAPER

Transforming the Fuel Retail Customer Journey

The global, randomised, open-label, multi-centre Phase III trial analysed the efficacy, safety and tolerability of Kymriah against standard-of-care (SOC) in patients enrolled at more than 73 sites in 18 countries.

Salvage chemotherapy was the SOC, which was followed by high-dose chemotherapy and hematopoietic stem cell transplant (HSCT) in responding subjects.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

[Continue](#) [Learn more](#)



stable disease at or following the week 12 analysis or death at any time.

Novartis noted that Kymriah's safety profile in the trial was in line with the previously reported data.

Novartis Oncology and Hematology Development global head Jeff Legos said: "Patients with aggressive B-cell non-Hodgkin lymphoma who are refractory to first-line treatment are vulnerable and we are disappointed that the BELINDA study did not meet its primary endpoint in this setting.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

[Continue](#) [Learn more](#)



Poll |

**In your opinion, what has
been the biggest impact of
the COVID-19 pandemic on
clinical trials?**

- Inability or delay to initiate clinical trials
- Suspension or termination of ongoing trials
- Withdrawal of planned trials before initiation
- Difficulty in enrolling subjects
- Missing a major development milestone
- Loss of investment
- Other

Next

“Kymriah continues to demonstrate durable responses for patients with certain advanced blood cancers in the third-line setting.”

The company noted that Kymriah is efficacious in currently approved indications and provides the potential for lasting responses and a favourable safety profile in clinical and real-

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

[Continue](#) [Learn more](#)



Earlier this year, Novartis reported that the primary analysis of the Phase II ELARA trial of Kymriah showed a complete response rate of 66% in relapsed or refractory follicular lymphoma patients.

The company is now working towards regulatory filings of the drug for follicular lymphoma in the second half of this year.

Related Companies

Experic

Contract Manufacturing Organisation and Pharmaceutical Supply Services



VaLea Clinical Trials

Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings



Malvern Panalytical

Biopharmaceutical and Drug Development



Up Next

NEWS

Antibody cocktail prevents Covid-19-related hospitalisations.

NEWS

SK bioscience-GSK Covid-19 vaccine candidate enters Phase

NEWS

Pfizer reports positive data from Phase III atopic dermatitis drug

NEWS

OPKO Health concludes subject enrolment in Phase II Covid-

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

[Continue](#) [Learn more](#)





The leading site for news and procurement in the clinical research industry

Receive our newsletter

Sign up to our e-Newsletter here

Enter your email address



About us
Editorial Approach
Contact Us

Privacy Policy
Terms and Conditions

© Copyright Verdict Media Limited 2021

Powered by VERDICT

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.



Continue Learn more